Oneness Biotech will proceed to unblind Phase 3 data of ON101 MRCT (protocol#ON101CLCT02) according to TFDA notification letter# 1096013906


  Oneness Biotech receives written notification by writing from Taiwan Food and Drug Administration under Letter#1096013906 to allow Phase 3 MRCT of ON101 (protocol#ON101CLCT02) to proceed with 2ndinterim statistical analysis as final results for Phase 3 trial.